Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Press Releases

Keyword Search

August 28, 2020
Ocugen to Present at the LD 500 Virtual Investor Conference
MALVERN, Pa., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced it will present at the LD 500 Virtual Investor Conference on Friday,
Additional Formats
PDF Version
August 14, 2020
Ocugen Provides Business Update and Second Quarter 2020 Financial Results
Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing
Additional Formats
PDF Version
August 10, 2020
Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy, for the Treatment of Another Key Inherited Retinal Disease (IRD), PDE6B Gene Mutation-Associated Retinal Diseases
Fourth orphan drug designation for the same product, OCU400, is distinct in Ophthalmology gene therapy and demonstrates its potential to treat many Inherited Retinal Diseases MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
Additional Formats
PDF Version
July 21, 2020
Ocugen to Present at World Orphan Drug Congress USA 2020 Conference
MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at the World Orphan Drug
Additional Formats
PDF Version
Displaying 1 - 10 of 18